A DLT was defined as the occurrence of any of the following treatment-emergent adverse events (TEAEs) during the DLT assessment window, unless equivocally due to underlying malignancy or an extraneous cause. AEs were graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0: non-hematologic toxicity: all non-hematologic TEAEs of grade 3 or greater with the exception of grade 3 nausea or vomiting that could be controlled by supportive therapy; hematologic toxicity: grade 4 neutropenia >5 days, grade 4 thrombocytopenia or grade 3 thrombocytopenia with bleeding event or requiring platelet transfusion, grade >=3 febrile neutropenia (defined as absolute neutrophil count [ANC] <1000/cubic millimeter {mm^3} with a single temperature >38.3 degree Celsius [°C] or a sustained temperature of >=38°C for more than 1 hour), grade 4 anemia not explained by underlying disease; any TEAE that required a dose delay of >=15 days; any case of Hy's Law.

The DLT evaluable analysis set (DEAS) was defined as all patients enrolled in the dose escalation stage of the study who were evaluable for DLT assessment. A patient was DLT evaluable if: had received at least 75% of the assigned dose of study drug during the DLT assessment window or had not completed the DLT assessment period due to a DLT.

An AE was any untoward medical occurrence in a clinical investigation patient administered a study drug, regardless of causal attribution. An SAE was an AE that resulted in any of the following: was fatal, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect in a neonate/infant born to a female patient or female partner of a male patient exposed to the study drug, or was considered a significant medical event by the investigator. TEAEs were defined as AEs with onset date on or after the first dose of study drug and no later than 30 days after the date of last study drug administration or start of a new study drug of anti-neoplasm therapy, whichever was earlier. Treatment related AEs and SAEs were defined as AEs and SAEs collected later than 30 days after the last study drug date or start of a new study drug of anti-neoplasm therapy.

The FAS included all patients who received at least 1 dose of HMPL-689.

An AE was any untoward medical occurrence in a clinical investigation patient administered a study drug, regardless of causal attribution. TEAEs were defined as AEs with onset date on or after the first dose of study drug and no later than 30 days after the date of last study drug administration or start of a new study drug of anti-neoplasm therapy, whichever was earlier. Treatment related AEs were defined as AEs collected later than 30 days after the last study drug date or start of a new study drug of anti-neoplasm therapy.

The FAS included all patients who received at least 1 dose of HMPL-689.

ORR: percentage of patients with complete response (CR),CR with incomplete marrow recovery (CRi),nodular partial response (nPR),PR with lymphocytosis (PR-L) or PR for CLL patients; CR, very good PR (VGPR),PR or minor response (MR) for WM patients;CR or PR for patients with disease other than CLL and WM.CR: absence of serum (S) monoclonal immunoglobulin (Ig)M, normal S IgM, complete resolution of extramedullary disease,morphologically normal bone marrow aspirate and trephine biopsy. CRi:criteria fulfilled for CR but persistent cytopenia,anemia,thrombocytopenia or neutropenia. nPR:patients with residual CLL cells.PR-L:patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy.PR, VGPR, MR: detectable monoclonal IgM,no new signs/symptoms of active disease and PR: ≥50% but <90% reduction in S IgM,reduction in extramedullary disease,VGPR: >=90% reduction in S IgM,complete resolution of extramedullary disease,MR: >=25% but <50% reduction in S IgM.

The efficacy analysis set (EAS) included all patients who received at least 1 dose of HMPL-689 and had a baseline tumor assessment and at least 1 evaluable post-baseline assessment unless death occurred before the first post-baseline assessment.

TTR was defined as the time from the first dose of study drug to the first occurrence of CR, CRi, PR, nPR, VGPR, PR-L, or MR. CR: absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. PR: detectable monoclonal IgM, no new signs/symptoms of active disease, 50% but <90% reduction in serum IgM, reduction in extramedullary disease. nPR: patients with residual CLL cells. VGPR: detectable monoclonal IgM, no new signs/symptoms of active disease,>=90% reduction in serum IgM, complete resolution of extramedullary disease. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. MR: detectable monoclonal IgM, no new signs/symptoms of active disease, >=25% but <50% reduction in serum IgM.

The EAS included all patients who received at least 1 dose of HMPL-689 and had a baseline tumor assessment and at least 1 evaluable post-baseline assessment unless death occurred before the first post-baseline assessment. Only patients with CR, CRi, PR, nPR, VGPR, PR-L, or MR were included in the analysis.

DOR: time from when first response (CR, CRi, PR, nPR, VGPR, PR-L and MR) was achieved until earlier of first documentation of definitive PD or death from any cause, whichever was earlier. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: ≥50% but <90% reduction in S IgM, reduction in extramedullary disease, VGPR: >=90% reduction in S IgM, complete resolution of extramedullary disease, MR: >=25% but <50% reduction in S IgM. PD: >=25% increase in S IgM level from lowest nadir and/or progression in clinical features attributable to the disease.

The EAS included all patients who received at least 1 dose of HMPL-689 and had a baseline tumor assessment and at least 1 evaluable post-baseline assessment unless death occurred before the first post-baseline assessment. Only patients with CR, CRi, PR, nPR, VGPR, PR-L, or MR were included in the analysis.

CBR was defined as percentage of patients who had best overall response (BOR) with stable disease (SD) or better. BOR was defined as the best response recorded from the start of treatment until PD or new anti-cancer therapy, whichever came earlier. PD: >=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease. SD: detectable monoclonal IgM, <25% reduction and <25% increase in serum IgM level, no progression in extramedullary disease, no new signs/symptoms of active disease.

The EAS included all patients who received at least 1 dose of HMPL-689 and had a baseline tumor assessment and at least 1 evaluable post-baseline assessment unless death occurred before the first post-baseline assessment.

PFS was defined as the time from the date of first study drug to the earliest date of PD or death of any cause, whichever occurred first. PD was defined as >=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease.

The FAS included all patients who received at least 1 dose of HMPL-689.

Blood samples were collected to determine plasma concentration of HMPL-689. The pharmacokinetic (PK) parameters were determined by non-compartmental analysis.

The pharmacokinetic analysis set (PKAS) included all patients who received at least 1 dose of HMPL-689 and had at least 1 PK sample obtained and analyzed. Only patients with data collected at specified timepoints are reported.

Blood samples were collected to determine Ctrough of HMPL-689. The PK parameters were determined by non-compartmental analysis.

The PKAS included all patients who received at least 1 dose of HMPL-689 and had at least 1 PK sample obtained and analyzed. Only patients with data collected at specified timepoints are reported.

Blood samples were collected to determine plasma concentration of HMPL-689. The PK parameters were determined by non-compartmental analysis.

The PKAS included all patients who received at least 1 dose of HMPL-689 and had at least 1 PK sample obtained and analyzed. Only patients with data collected at specified timepoints are reported.

Blood samples were collected to determine Ctrough of HMPL-689. The PK parameters were determined by non-compartmental analysis.

The PKAS included all patients who received at least 1 dose of HMPL-689 and had at least 1 PK sample obtained and analyzed. Only patients with data collected at specified timepoints are reported.

12-lead electrocardiogram was performed to evaluate the effect of HMPL-689 on cardiac repolarization by detecting the changes in QTcF intervals. Baseline was defined as the last assessment performed prior to or on first non-zero dose date with time point marked as "pre-dose".

The FAS included all patients who received at least 1 dose of HMPL-689. As pre-specified in the protocol, the results are presented by dose level and combined data for dose expansion stage is presented for all patients evaluable for this endpoint who received HMPL-689 at RP2D (30 mg QD) in dose expansion stage. Only patients with data collected at specified timepoints are reported.